Guardant Health (NASDAQ:GH) Trading Up 9.8% - What's Next?

Guardant Health, Inc. (NASDAQ:GH - Get Free Report)'s stock price shot up 9.8% during mid-day trading on Tuesday . The stock traded as high as $39.77 and last traded at $39.34. 275,606 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 2,115,893 shares. The stock had previously closed at $35.84.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a report on Monday, February 24th. Scotiabank increased their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Guggenheim reaffirmed a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. Barclays began coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price target on the stock. Finally, Stifel Nicolaus raised their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health has an average rating of "Buy" and an average price target of $48.40.

Guardant Health Stock Up 13.8 %

The firm has a market capitalization of $5.03 billion, a P/E ratio of -11.45 and a beta of 1.50. The business's 50 day moving average is $42.06 and its 200-day moving average is $32.46.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now directly owns 2,676 shares of the company's stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 2,668 shares of company stock worth $95,208 in the last three months. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in shares of Guardant Health by 188.6% in the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock valued at $232,325,000 after buying an additional 6,618,785 shares during the period. Norges Bank bought a new stake in Guardant Health in the fourth quarter valued at approximately $36,438,000. Two Sigma Advisers LP increased its position in Guardant Health by 96.7% during the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after purchasing an additional 1,138,300 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in Guardant Health by 1,282.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock worth $28,128,000 after purchasing an additional 1,137,482 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new position in shares of Guardant Health in the 3rd quarter worth approximately $21,389,000. 92.60% of the stock is owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.